Original Article

Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma

Ming-Chin Yu a,b,g, Tsung-Han Wu a,g, Chao-Wei Lee a,g, Yun-Shien Lee c,d, Jang-Hau Lian c, Chia-Lung Tsai c, Sen-Yung Hsieh e,g, Chi-Neu Tsai a,f,g,*

a Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
b Department of Surgery, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
c Genomic Medicine Research Core Laboratory, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
d Department of Biotechnology, Ming-Chuan University, Taoyuan, Taiwan
e Department of Gastroenterology and Hepatology at Linkou, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
f Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
g College of Medicine, Chang Gung University, Taoyuan, Taiwan

Article info

Article history:
Received 7 September 2019
Accepted 13 July 2020
Available online 15 July 2020

Keywords:
Advanced HCC
Sorafenib
Copy number aberrations
7q amplification
ABCB1

Abstract

Background: Hepatocellular carcinoma (HCC) may arise from genomic instability and has dismal outcome. Sorafenib is the first-line treatment for advanced stage HCC, but its therapeutic efficacy is less than 50%. Biomarkers for predicting the therapeutic efficacy of sorafenib administration to patients with advanced HCC are required. Here, we evaluated the role of chromosomal copy number aberrations (CNAs) in patients with advanced HCC who were treated with sorafenib along with their drug response.

Methods: The response to sorafenib treatment of twenty-three HCC patients who developed advanced recurrence after partial hepatectomy was analyzed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Formalin fixed paraffin embedded (FFPE) tissue specimens obtained after tumor resection were analyzed using the Affymetrix OncoScan® FFPE assay.

Results: From the 23 patients analyzed in this study, 7 (30.4%) had complete/partial response to sorafenib (CR/PR), 7 (30.4%) had stable disease (SD), and 9 (39.1%) had progressive disease (PD). The mean genome-wide percentage of genome change acquisition via the OncoScan platform was 19.8% for patients with CR/PR/SD and 50.02% in the PD group (p = 0.055). Percentage of genome change above 33% was associated with adverse outcomes for sorafenib treatment in the time-to-progression analysis (p = 0.007) and overall survival (p = 0.096). Among these CNAs, amplification of chromosome 7q, containing the multidrug resistance gene ATP Binding Cassette Subfamily B Member 1 (ABCB1), significantly associated with poor overall survival (p = 0.004) and time-to-progression (p < 0.001).

* Corresponding author. Graduate Institute of Clinical Medical Sciences, Chang Gung University, 259, Wenhu 1st Rd. Gueishan, Taoyuan 333, Taiwan.
E-mail address: pink7@cgu.edu.tw (C.-N. Tsai).
Peer review under responsibility of Chang Gung University.
https://doi.org/10.1016/j bj.2020.07.001
2319-4170/© 2020 Chang Gung University. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
At a glance of commentary

Scientific background

Sorafenib is the first-line treatment for advanced stage HCC, but its therapeutic efficacy is less than 50%. Therefore, biomarkers for predicting the therapeutic efficacy of sorafenib administration to patients with advanced HCC are still required.

What this study adds to the field

In this report, tumor specimen with higher percentage genome change and amplification of chromosome 7q containing ABCB1 drug resistant gene in advanced HCC was associated with sorafenib resistance, which might be applied for copy number analysis before drug administration after partial hepatectomies in these patients.

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. The major risk factors for HCC are chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV), alcohol intake, smoking, and toxin exposure [1,2]. Curative treatment, including a partial hepatectomy, ablation therapy, and liver transplantation at an early stage, lead to the best outcome, but the risk of recurrence is still more than 50% [3–6]. Most recurrences are intrahepatic; however, some patients develop disseminated spreading or distant metastasis and require systemic treatment [7]. The poor prognosis after HCC resection may arise from increased genomic instability [4,8,9]. Besides, early recurrence has a dismal outcome and, thus, there is an increased need for the development of effective adjuvant therapies [10]. Combined treatment with sorafenib and transcatheter arterial chemembolization (TACE) was a well-tolerated and efficacious strategy for Barcelona Clinic Liver Cancer (BCLC) stage B in START trials [11]. Although systemic targeted therapy with sorafenib has been assumed as a standard treatment for advanced HCC, a precise and personalized approach is necessary to improve survival [12].

Sorafenib is a multikinase inhibitor that targets the vascular endothelial growth factor receptor (VEGFR), the platelet-derived growth factor receptor (PDGFR), and the downstream RAF/mitogen-activated protein/extracellular signal-regulated kinase (MAPK)/ERK) cascade [13]. The antiproliferative and antiangiogenic effects of sorafenib reduce tumor growth in several kinds of cancers [13]. The real world treatment showed that half of the patients treated with sorafenib had progressive disease and their quality of life did not benefit because of sorafenib resistance [14]. There are several theories regarding sorafenib resistance: extrahepatic spreading and occurrence of intolerant adverse events [15]; escape of cancer stem cells from treatment-induced apoptosis, leading to tumor repopulation [16]; activation of hypoxia-inducible factor 1 after sorafenib treatment and the subsequent induction of angiogenesis, immune escape, and autophagy in the tumor [17]; activation of the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway; and enhancement of epithelial–mesenchymal transition (EMT) [18]. Suppression of the RAF/MEK/ERK signaling pathway and induction of cell cycle arrest in the G2/M phase could help treatment in patients with sorafenib resistance [19]. Changes in the tumor microenvironment has been proven to be correlated with sorafenib resistance [20,21]. Chromosome instability and CNAs in HCC and other solid tumors could lead to the activation of oncogenes and the inactivation of tumor suppressor genes, which induce changes in transcription, translation, and tumor invasiveness [8,9]. A recent study has shown that genome-wide CNAs and VEGFA amplification in circulating cell-free DNA were a biomarker for advanced HCC in patients treated with sorafenib [22]. In addition, Fibroblast Growth Factor 3 and 4 (FGF3/4) amplification detected via fluorescence in situ hybridization was associated with lung metastases in sorafenib-treated advanced HCC patients [23]. Amplification of FGFR1 has also been reported to be associated with sorafenib response in advanced HCC using next generation sequencing and copy number assay [24]. Therefore, genome instability has been strongly associated with sorafenib treatment response in advanced HCC patients; systematic analysis of CNAs in tumor specimens of patients would improve the survival of patients.

In this study, we assessed the role of chromosomal CNAs in patients with advanced HCC who were treated with sorafenib and also evaluated their drug response. Twenty-three HCC patients had undergone surgical resection and showed advanced recurrence. FFPE tumor specimens of HCC at advanced recurrence. All recurrence was treated with sorafenib [20,21]. Twenty-three HCC patients had undergone surgical resection and showed advanced recurrence. FFPE tumor specimens of HCC at advanced stage, involved portal vein thrombus (PVT) or extrahepatic spreading (EHS). All patients enrolled was in good performance status with ECOG score between 0 and 1.

Patients and methods

Patients and samples

This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital (CGMH), Linkou (IRB 201600707/B0C501). Twenty-three HCC patients had curative treatment and developed HCC recurrence. All recurrence was at advanced stage, involved portal vein thrombus (PVT) or extrahepatic spreading (EHS). All patients enrolled was in good performance status with ECOG score between 0 and 1.
and Child-Pugh A status, then sorafenib based combination treatment was started. The clinical and pathological variables were collected for analysis and the long-term outcome was compared with log-rank test and Kaplan–Meier survival analysis. The response to sorafenib was measured according to the modified RECIST as best clinical response; complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) [25]. The operation FFPE specimens were processed for genomic DNA extraction and OncoScan genechip analysis.

DNA extraction and FFPE sample gene chips analysis

The genomic DNA extraction and data processing after Affymetrix OncoScan genechip hybridization were performed as previously described [9]. The FFPE genomic DNA was extracted using the QiAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. DNA samples were further processed at the Genomic Medicine Research Core Laboratory in CGMH for Affymetrix OncoScan® FFPE assay (Santa Clara, CA, United States) to analyze copy number aberrations (CNAs), loss of heterozygosity (LOH), and somatic mutations [26]. The data were analyzed by the Nexus Copy Number software included in the Affymetrix OncoScan FFPE Express Service (Biodiscovery). The percentage genome change showed the number of CNAs of each patient divided by the total of 875 genes designed in OncoScan platform.

Immunohistochemistry

The FFPE specimen were sectioned to 4 µm in thickness and de-paraffinized, rehydrated, and processed for antigen retrieval. The slides were further incubated with appropriate dilutions of the selected antibodies at room temperature for 1–2 h. After incubation, the slides were washed three times in phosphate-buffered saline (PBS), incubated with a horse red-dish peroxidase conjugated antibody polymer (Zymed) at room temperature for 10 min, and were then developed by phosphate-buffered saline (PBS), incubated with a horse red-dish peroxidase conjugated antibody polymer (Zymed) at room temperature for 10 min, and were then developed by 3,3'-diaminobenzidine (Roche) at room temperature for 10 min. The titer for ABCB1 (Wuhan Fine Biotech, F Nab09805), EGFR (Zeta Corporation, clone EP22) and BRAF (Abcam) was 1:500, 1:500 and 1:100, respectively. The percentage genome change was increased in the tumor chromosome 7q in HCC patients with PD, and the clinical treatment response of patients was poor when the global genomic alterations in recurring HCC were analyzed using the Affymetrix OncoScan® FFPE assay with 875 oncogenes or tumor suppressor genes. CNAs, upon virtual karyotyping of chromosomes showed a remarkable difference in amplification in patients with CR/PR, SD, and PD treatment responses. However, there was a significant increase in amplification in chromosome 7q in HCC patients with PD, and the clinical treatment response of patients was poor when the global percentage genome change was increased in the tumor specimen [Fig. 2]. The comparison between patients with low and high percentage genome change (≤33.0% and >33.0%, respectively) is shown in Table 2. There was no difference in clinical staging and demographic data but the percentage genome change and disease control rate (DCR) were different. The log-rank test indicated there was borderline difference in overall survival between high and low percentage genome change (p = 0.096) but the time-to-progression analysis indicated a significantly better outcome in patients with low percentage genome change (p = 0.004) [Fig. 3A and B], which indicated higher percentage genome change in tumor

Results

The best clinical response was associated with the long term-outcome

Of the 23 patients who were administered sorafenib, 7 (30.4%) showed CR/PR, 7 (30.4%) showed SD, and 9 (39.1%) presented PD in the evaluation of best clinical response [Fig. 1] [Table 1]. The mean age of the patients was 58.7 ± 11.2 years and 22 (95.7%) patients were male. Four patients (17.4%) had stage III HCC and 19 (82.6%) had stage IV HCC. The most common extrahepatic spreading was to bone, lung, and lymph nodes [Table 1]. The mean duration of treatment (DOT) was 12.2, 34.9, 6.8, and 2.73 months in CR, PR, SD, and PD, respectively. The typical sorafenib response in patients with advanced HCC is shown in Fig. 1A–C. The Kaplan–Meier survival curve for patients with advanced HCC treated with sorafenib and the log-rank test indicated a better outcome when the treatment response was CR/PR (tumor shrinkage) as compared with PD and SD (p = 0.003) [Fig. 1D]. There is no significant difference by log rank tests for combination treatment, radiotherapy (RT) and transarterial chemoembolization (TACE) in overall survival (p = 0.777, 0.119 and 0.120; respectively).

Application of percentage of genome changes for sorafenib response in advanced HCC after resection

All patients with HCC recurrence administered sorafenib were at an advanced HCC stage, with portal vein thrombus (PVT) or extrahepatic spreading (EHS) involvement. Global genomic alterations in recurring HCC were analyzed using the Affymetrix OncoScan® FFPE assay with 875 oncogenes or tumor suppressor genes. CNAs, upon virtual karyotyping of chromosomes showed a remarkable difference in amplification in patients with CR/PR, SD, and PD treatment responses. However, there was a significant increase in amplification in chromosome 7q in HCC patients with PD, and the clinical treatment response of patients was poor when the global percentage genome change was increased in the tumor specimen [Fig. 2]. The comparison between patients with low and high percentage genome change (≤33.0% and >33.0%, respectively) is shown in Table 2. There was no difference in clinical staging and demographic data but the percentage genome change and disease control rate (DCR) were different. The log-rank test indicated there was borderline difference in overall survival between high and low percentage genome change (p = 0.096) but the time-to-progression analysis indicated a significantly better outcome in patients with low percentage genome change (p = 0.004) [Fig. 3A and B], which indicated higher percentage genome change in tumor

Statistical analysis

Categorical data were analyzed using the chi-square test or Fisher’s exact test. Continuous variables were analyzed using with Mann–Whitney U test due to the limited cases without normal distribution in this study. Survival rates in each group were determined by the Kaplan–Meier method and differences between groups were analyzed using log-rank test. The best cut-off value was estimated using the Youden index for maximizing the sum of sensitivity and specificity to discriminate different events. Statistical analyses were performed using SPSS statistical software version 19.0 (SPSS, Inc., Chicago, IL, United States).
specimen of advance HCC indicate adverse prognosis after sorafenib treatment.

**Karyotyping analysis of sorafenib response in advanced HCC**

The analysis of amplifications and deletions in 875 genes listed in the Affymetrix OncoScan® FFPE assay showed there was a significant increase of amplification at chromosome 7q associated with sorafenib resistance [Table 3]. HCC patients with PD after sorafenib administration had more than 75% amplification at chromosome 7; especially the amplification of 7q21.12-7q31.2 was the most significantly associated with treatment failure [Fig. 2] [Table 3]. Only one patient had chromosome 7q amplification in the CR/PR/SD group. These results imply that the drug response was possibly related to the amplification. Within the amplification region, 7q21.12-7q31.2, was the ATP Binding Cassette Subfamily B Member 1 (ABCB1) gene, which functions as an ATP-dependent drug efflux pump and has been reported to be associated with multidrug resistance in several kinds of cancers [27,28]. Cyclin Dependent Kinase 6 (CDK6) has been reported to play a role in the proliferation of cancer cells [29]. Besides 7q21.12-7q31.2, other region in chromosome 7 contains epidermal growth factor receptor (EGFR) and INHBA, which may trigger the MAPK/ERK and PI3K pathways [18,30]. Respectively, and play a role in cell survival, were also amplified in the sorafenib resistant patients. Moreover, the amplification of chromosome 7q was significantly associated with poor outcome in overall survival and time-to-progression analyses [Fig. 3C and D, $p = 0.004$ and $p < 0.001$, respectively]. Therefore, CNA changes in the tumors of patients with advanced HCC may increase the activity of the ATP-dependent drug efflux pump, cell survival, and cell proliferation, establishing resistance to sorafenib treatment.

To correlate whether the amplification of 7q21.12-7q31.2 was associated with elevated its protein level, the expression of ABCB1, EGFR, and BRAF [list on Table 3] were examined via immunohistochemistry in tumor FFPE specimen of seven cases. Even amplification in chromosome 7q21.12-7q31.2 in these cases, the heterogeneity still existed in each specimen; some of specimen containing whole 7q21.12-7q31.2 amplification, some specimen containing only ABCB1, or EGFR amplification [Fig. 4]. Overall speaking, the amplification of ABCB1 region had relatively higher protein expression than those without ABCB1 amplification [Fig. 4], which might be the result for treatment failure.

In summary, the treatment response for sorafenib for recurring HCC could be possibly predicted before drug treatment via acquisition of global CNAs in the tumor tissue using the OncoScan platform. Higher percentage genome change or amplification in chromosome 7q (containing ABCB1 amplification) in tumor specimen of advance HCC indicate resistance to the drug sorafenib.

**Discussion**

It is still necessary to develop prognostic biomarkers to determine the efficacy and cost-effectiveness of sorafenib...
Table 1 Clinical response to sorafenib administration in HCC patients who underwent partial hepatectomy and have recurrent disease.

| No | CNA (%) | Age | Sex | Stage at diagnosis | Stage at recurrence | Target site | Dosage | DOT | Treatment/combination | Best Clinical Response | Mortality | Survival |
|----|---------|-----|-----|--------------------|--------------------|-------------|--------|-----|-----------------------|------------------------|-----------|----------|
| 1  | 10.3    | 53  | M   | I                  | IV                 | Bone        | 600    | 2.1 | SORA/RT               | PD                     | Yes       | 7.8      |
| 2  | 14.8    | 45  | M   | I                  | IV                 | IVC, PV, HV, adrenal | 800    | 1.8 | SORA                  | PD                     | Yes       | 1.8      |
| 3  | 29.2    | 56  | M   | I                  | IV                 | Bone, Liver | 800    | 2.4 | SORA/RT               | PD                     | Yes       | 12.3     |
| 4  | 34.3    | 39  | M   | I                  | IV                 | Lung, Bone  | 600    | 2.8 | SORA/RT               | PD                     | Yes       | 14.6     |
| 5  | 36.9    | 65  | M   | I                  | IV                 | Duodenum    | 400    | 2.3 | SORA/RT               | PD                     | Yes       | 3.1      |
| 6  | 38.4    | 57  | M   | I                  | IV                 | Bone        | 600    | 1.6 | SORA                  | PD                     | Yes       | 23.6     |
| 7  | 48.7    | 66  | M   | I                  | IV                 | IVC, HV, adrenal | 400    | 2.3 | SORA                  | PD                     | Yes       | 33.3     |
| 8  | 60.7    | 49  | M   | I                  | IV                 | Lung, IVC   | 600    | 6.4 | SORA                  | PD                     | Yes       | 7.0      |
| 9  | 77.2    | 57  | M   | I                  | III                | MHV         | 800    | 2.7 | SORA/RT               | PD                     | Yes       | 8.0      |
| 10 | 17.8    | 74  | M   | I                  | IV                 | Bone        | 400    | 7.8 | SORA/RT               | SD                     | Yes       | 13.3     |
| 11 | 19.6    | 43  | M   | I                  | IV                 | LN, PVT     | 600    | 4.8 | SORA/TACE, RT         | SD                     | Yes       | 7.0      |
| 12 | 29.2    | 70  | M   | II                 | IV                 | Pleura      | 800    | 1.2 | SORA/RT               | SD                     | Yes       | 66.3     |
| 13 | 30.2    | 59  | M   | I                  | III                | Liver       | 400    | 1.2 | SORA                  | SD                     | Yes       | 14.0     |
| 14 | 33.0    | 62  | M   | I                  | III                | Liver       | 600    | 14.3 | SORA/TACE             | SD                     | Yes       | 14.3     |
| 15 | 36.1    | 72  | M   | I                  | IV                 | LN          | 400    | 5.8 | SORA                  | SD                     | Yes       | 19.6     |
| 16 | 36.4    | 48  | M   | I                  | IV                 | Lung        | 600    | 1.7 | SORA                  | SD                     | Yes       | 7.3      |
| 17 | 0.3     | 55  | M   | I                  | III                | Liver       | 200    | 3.34 | SORA/OP               | PR                     | Yes       | 65.5     |
| 18 | 11.8    | 42  | F   | II                 | IV                 | LN          | 400    | 72.6 | SORA                  | PR                     | Yes       | 72.6     |
| 19 | 20.8    | 65  | M   | I                  | IV                 | LN          | 400    | 7.3 | SORA                  | PR                     | Yes       | 8.5      |
| 20 | 28.0    | 79  | M   | I                  | IV                 | Lung        | 600    | 26.3 | SORA                  | PR                     | Yes       | 26.3     |
| 21 | 23.5    | 54  | M   | I                  | IV                 | Lung        | 600    | 5.8 | SORA/OP               | CR                     | Yes       | 21.5     |
| 22 | 28.5    | 65  | M   | II                 | IV                 | Bone, Liver | 600    | 11.4 | SORA/RT, TACE         | CR                     | Yes       | 63.7     |
| 23 | 31.6    | 74  | M   | II                 | IV                 | Lung, Sternum | 400    | 19.4 | TACE, SORA            | CR                     | Yes       | 63.2     |

Abbreviations: CNA (%): percentage of genome change in copy number aberration; DOT: duration of treatment; SORA: sorafenib; RT: radiotherapy; CT: chemotherapy; TACE: transarterial chemoembolization.

* Liver transplantation.

* Lung lobectomy for solitary lesion.

* Stable state after radiotherapy.
Elevated levels of the hepatocyte growth factor (HGF), phosphorylated-ERK (p-ERK), and c-Jun have been reported to contribute to the poor response to sorafenib. However, cancer genetic heterogeneity influences the clinical application of these biomarkers as predictors of the response to sorafenib. In our study, amplification of chromosome 7, including \( \text{ABCB1, EGFR, BARF, and } \text{MET} \), the upstream receptor kinases for activation of p-ERK and c-Jun, was found in the sorafenib resistant group [Table 3]. The expression of EGFR was not evaluated in these twenty-three patients via immunohistochemistry; therefore, we could not confirm whether EGFR and its downstream RAF/MEK/ERK pathway were activated in sorafenib resistant patients [36]. In a previous study, inhibition of the PI3K/Akt pathway reversed sorafenib resistance in HCC cells, indicating that combinatorial treatment would promote sorafenib treatment efficacy [18,37]. Interestingly, amplification of \( \text{INHBA} \) (encoded activin A) was also found to be associated with sorafenib response in advanced HCC patients [Table 3]. Overexpression of activin A stimulated the non-canonical pathway PI3K/akt signaling to promote cell migration [30]. Therefore, amplification of chromosome 7 contributed to the characteristics of sorafenib resistant HCC cells. Besides, the quantitation of chromosomal alterations as the percentage of genome changed via the
### Table 2 Comparison of the clinical characteristics of two groups of the 23 patients with advanced HCC created using a percentage genome change cut off value of 33%.

| Percent genome change ≤33.0% (n = 15) | Percent genome change >33.0% (n = 8) | P     |
|----------------------------------------|--------------------------------------|-------|
| Age (years)                            | 59.7 ± 11.6                          |       |
| Sex (male)                             | 14 (93.3%)                           | 56.6 ± 10.9 | 0.651 |
| Stage (Diagnosis) II                   | I 4 (26.7%)                          | II 0 (0%) | 0.154 |
| I 11 (73.3%)                           |                                     | I 8 (100.0%) |       |
| Stage (Recurrence) IV                  | IV 12 (80.0%)                        | IV 7 (87.5%) | 0.565 |
| III 3 (20.0%)                          |                                     | III 1 (12.5%) |       |
| AFP (ng/ml)                            | 96.0 ± 173.3                         | 8379.9 ± 23287.9 | 0.071 |
| CNA (%)                                | 21.9 ± 9.5                           | 46.1 ± 15.4 | <0.001*** |
| Dosage ≥600 mg                         | 9 (60.0%)                            | 5 (62.5%) | 0.633 |
| DCR (%)                                | 7 (46.7%)                            | 0 (0%) | 0.026* |

Abbreviations: AFP: alpha-fetoprotein; DCR: disease control rate. Age, CNA, and AFP are presented as mean ± S.D. Sex, stage, Dosage≥600 mg and disease control rate (DCR) are presented as number of cases (percentage). *P<0.05, ***P<0.001.

---

**Fig. 3** The percentage genome change and amplification of chromosome 7q in overall survival and time-to progression analysis (A). The cut-off of percentage genome change for outcome prediction was set at ≤33.0% vs. >33.0% and the log-rank test showed no significant difference although it showed a tendency for the same (p = 0.096). (B) The time-to-progression analysis indicated a significantly better outcome when percentage genome change was <33% (black solid line) (p = 0.004). (C) The amplification of chromosome 7q (dotted line) was significantly associated with poor outcome in overall survival (p = 0.004). (D) The amplification of chromosome 7q (dotted line) was significantly associated with poor survival in the time-to-progression analysis. (p < 0.001).
Affymetrix OncoScan® FFPE assay for each HCC patient tumor specimen could predict drug responsiveness to sorafenib, which may be applied before drug administration after partial hepatectomies in these patients.

ABCB1 amplification and single nucleotide polymorphisms have been associated with multiple drug resistance in several kinds of cancers [27,28]. Resistance to doxorubicin and 5-fluorouracil have been associated with overexpression of ABCB1 in HCC tumor tissues. Additionally, some reports have suggested that combination with a specific ABCB1 inhibitor would increase sensitivity to drugs [38]. However, the ABCB1 polymorphism 3435C>T was significantly associated with the lowest sorafenib plasma levels and, thus, with a better therapeutic response [39]. In our study, the amplification of ABCB1 was significantly associated with resistance to sorafenib. This is the first report showing the correlation between amplification of ABCB1 and sorafenib resistance in advance HCC patients.

Based on previous reports, amplifications of VEGFA, FGF3/FGF4, and FGF19 have been reported to be associated with sorafenib response in advanced HCC using different detection methods [22–24]. As shown in supplementary Table 1, amplification of VEGFA, FGF3, FGF4, and FGF19 in the SD, PD and PR/CR groups resulted in no statistically significant difference between them upon analysis of OncoScan data; however the probes in FGF3/4 and FGF19 were limited in the Affymetrix OncoScan® FFPE assay platform. The amplification of VEGFA was also not associated with the sorafenib response; however, the difference of this result with those of other studies might be due to differences in analysis platforms or patient-inclusion criteria. Meanwhile, the amplification or loss of RPPH1 (RNase P) was also found in our data (supplementary Table 1). The copy number of RPPH1 is frequently used as an internal control (reference) in commercial copy number assays. Among the 23 cases assessed here, RPPH1 was amplified in several cases with PD; this could have resulted in a lack of observed ABCB1 amplification in the analysis of CNAs through copy number PCR assay. Therefore, the internal controls for normalization of copy number PCR results should be carefully chosen.

The limited number of cases analyzed in this study could lead to potential bias and, thus, the results should be carefully interpreted. Further studies using well-designed large cohort could help validate our results.
Conclusion

Although the enrolled case number in this study was limited, the following conclusions could be drawn:

1. The treatment failure for sorafenib could be possibly predicted via higher percentage genome changes in tumor specimen acquisition from Affymetrix OncoScan platform.
2. Among these CNAs, amplification in chromosome 7q that containing drug resistant gene ACBC1 in tumor specimen tend to resistant to Sorafenib.
3. From tumor specimen of patients with HCC could predict drug responsiveness to sorafenib, which may be applied before drug administration after partial hepatectomies in these patients.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

We are grateful for the technological support of the Department of Cancer Center and Genomic Medicine Research Core Laboratory, Chang Gung Memorial Hospital, Linkou branch.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bj.2020.07.001.

Financial support

The study was supported by Chang Gung Memorial Hospital CMRP3F1993 and CMRPG1H0131 for Dr. Yu MC; CMRPD1G0611 and CMRPD1H0661 for Dr. Tsai CN.

References

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates

![Fig. 4 The expression of ABCB1, EGFR and BRAF in four representative cases were examined via immunohistochemistry in tumor FFPE specimen. The copy number changes in each gene within patient was as described. Amp: amplification (copy number >2), normal (copy number = 2). The staining density of ABCB1, EGFR was higher in specimen with copy number amplification than those are without amplification. The magnification of left three panel was 100X, whereas the magnification of the right panel (BRAF) was 200X.](image-url)
of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018;68:394–424.

[2] Sartorius K, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and county underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol 2015;39:284–90.

[3] Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753–8.

[4] Shah SA, Cleary SP, Wei AC, Yang J, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330–9.

[5] Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C, et al. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma. J Clin Gastroenterol 2013;47:871–80.

[6] Tu JC, Huang YH, Chau GY, Wu CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatits B-related hepatocellular carcinoma. J Hepatol 2009;51:890–7.

[7] Hayashi M, Shimizu T, Hirokawa F, Inoue Y, Komeda K, Asakuma M, et al. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma. Am Surg 2011;77:572–8.

[8] Cho HJ, Kim SS, Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Sorafenib in adjuvant setting: call for precise and molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma. Dig Dis 2015;33:771–9.

[9] Yu MC, Lee CW, Lee YS, Lian JH, Tsai CL, Liu YP, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for Research and treatment of cancer, national cancer Institute of the United States, national cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.

[10] Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genom 2009;2:8.

[11] Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C, et al. Autophagy 2011;7:1159–72.

[12] Zhang H, Wang Q, Liu J, Cao H. Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemoresistance in hepatocellular carcinoma. Oncol Lett 2018;15:9377–84.
[35] Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, et al. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Med 2017;6:2787–95.

[36] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol 2018;12:3–20.

[37] Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL, De Toni EN. The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Dis 2019;5:86.

[38] Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updates 2017;32:23–46.

[39] Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, Noe G, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Canc Chemother Pharmacol 2017;79:759–66.